Streetbeat News

Price Targets

BIIB

Biogen Inc reported better-than-expected Q3 earnings, with adjusted EPS of $4.08 and sales of $2.47 billion, both beating consensus estimates. Despite raising its 2024 EPS guidance, Biogen's stock fell 2.5% as analysts adjusted their price targets, with Morgan Stanley downgrading the stock.

Portfolio Pulse from Avi Kapoor

October 31, 2024 | 5:28 pm

ALKT

COIN

EAT

HSY

HUBG

META

MSFT

RIOT

WM

XPO

Top Wall Street analysts have updated their price targets for several companies, including Meta Platforms, Hub Group, Brinker International, Microsoft, XPO, The Hershey Company, Coinbase Global, Riot Platforms, Waste Management, and Alkami Technology. Notably, Mizuho raised Meta Platforms' price target, indicating a potential 33% rally.

Portfolio Pulse from Avi Kapoor

October 31, 2024 | 5:20 pm

CVNA

Carvana Co. (NYSE:CVNA) reported strong Q3 results, surpassing revenue and earnings expectations. The company anticipates further growth in Q4 and raised its full-year adjusted EBITDA guidance. Analysts have increased their price targets for Carvana, reflecting optimism about its future performance.

Portfolio Pulse from Avi Kapoor

October 31, 2024 | 5:20 pm

ALHC

TD Cowen analyst Gary Taylor maintains a Buy rating on Alignment Healthcare (NASDAQ:ALHC) and raises the price target from $10 to $13.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 5:15 pm

LAB

TD Cowen analyst Daniel Brennan maintains a Buy rating on Standard BioTools (NASDAQ:LAB) but lowers the price target from $2.75 to $2.5.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 5:11 pm

AEIS

Advanced Energy Industries (NASDAQ:AEIS) has been analyzed by four analysts, showing a range of perspectives from bullish to bearish. The average 12-month price target has increased by 9.95% to $113.25. Analysts have adjusted their ratings and price targets, reflecting recent market conditions and company performance. Despite revenue challenges, AEIS shows strong profitability with a net margin of 4.12% and effective use of equity and assets. However, the company faces challenges in managing its high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 5:05 pm

BIIB

TD Cowen analyst Phil Nadeau maintains a Buy rating on Biogen but lowers the price target from $300 to $275.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 5:04 pm

IRTC

Analysts have mixed ratings for iRhythm Technologies (NASDAQ:IRTC), with a majority being bullish. The average 12-month price target has decreased by 13.32% to $99.33. Recent analyst actions include both upgrades and downgrades of price targets, reflecting dynamic market conditions.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 5:04 pm

RIOT

In the past three months, 8 analysts have rated Riot Platforms (NASDAQ:RIOT), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target is $16.0, down 5.1% from the previous $16.86. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. Riot Platforms, a Bitcoin mining company, faces challenges with revenue growth, net margin, ROE, and ROA, but maintains a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 5:03 pm

AUR

TD Cowen analyst Jeffrey Osborne maintains a Hold rating on Aurora Innovation (NASDAQ:AUR) and raises the price target from $3 to $4.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 4:42 pm